GlassScriptPhysician profile
Meredith Donahue
NPI 1669948634
$7,810.73
in general payments reported to CMS, 2019-2025
14 companies · $5,040 in 2025
The $5,040 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $289 · 2023: $978 · 2024: $1,027 · 2025: $5,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,508 · Food and Beverage: $2,913 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $595 · Travel and Lodging: $29.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,507.50 |
| Food and Beverage | $2,912.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $595.00 |
| Travel and Lodging | $29.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,162.70 | 2021-2025 | Erleada, Akeega, Rybrevant |
| Photocure INC | $1,204.30 | 2023-2025 | Cysview |
| Urogen Pharma, INC. | $572.08 | 2021-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $406.04 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $404.37 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $306.18 | 2024-2025 | Adstiladrin |
| Procept Biorobotics Corporation | $149.45 | 2025 | |
| Myovant Sciences INC. | $138.55 | 2021-2022 | |
| Genzyme Corporation | $121.30 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $99.26 | 2025 | |
| Karl Storz Endoscopy-America | $77.68 | 2022 | |
| Astellas Pharma Global Development | $72.09 | 2023 | Xtandi |
| Immunitybio, INC. | $67.45 | 2024 | |
| Progenics Pharmaceuticals, INC. | $29.28 | 2023 | Pylarify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Donahue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.